Pipeline
Initial R&D portfolio
G Life Quantum is pursuing advanced research activities in multiple fields
* Endovascular systemic blood treatment
* Extravascular systemic blood treatment
* Cardio-protection & regeneration photonic intramyocardial therapy
* Cardio-protection & regeneration photonic endomyocardial therapy
* Stimulation of autologous mitochondrial transplantation
* Cell and stem cell stimulation therapies
Protection and optimization of mitochondrial respiratory function
Myocardial infarction is one of the most common acute conditions worldwide and a major cause of mortality.Current treatments have only limited effectiveness and can cause cardiomyocyte death up to several days after treatment.
Optimized photonic dosing through QBM may help precondition the heart muscle after hypoxia, potentially preparing it for reoxygenation.
Anti-inflammatory and immunomodulatory effects
QBM has shown anti-inflammatory and immunomodulatory effects. G Life Quantum develops QBM therapies in the blood that may impact endothelial cell protection and have effects on the cellular metabolism of circulating blood components, which help control the inflammatory and immune response.
Anti-platelet activity
G Life Quantum researchers have finalized the protocol for a Phase I clinical study investigating whether increased nitric oxide (NO) availability may reduce platelet aggregation.
Anti-hypoxemic action
QBM has been reported to affect hemoglobin, oxygen saturation and nitric oxide (NO) levels in the blood. G Life Quantum researchers have measured and quantified these phenomena in real time in the pulmonary and systemic circulations.